If you or someone close to you are affected by spinal muscular atrophy, please help to advocate for wide access to Spinraza in the UK.
Today members of TreatSMA and their children attended a Fast Track Treatment Campaign meeting organised by Muscular Dystrophy UK at the House of Commons.
The National Institute for Health and Care Excellence (NICE) announced that it will appraise Spinraza as a treatment for all those with spinal muscular atrophy
On 2 January 2018 all mailboxes of TreatSMA were suspended by Google without warning. As a result, the TreatSMA team lost access to all emails, address books and shared documents which until then were hosted on Google’s G Suite service.
The Scottish Medicines Consortium (SMC) will shortly start assessing nusinersen (Spinraza™) for use in NHS Scotland for the treatment of SMA Types 1, 2 and 3.